April 28th 2025
Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.
Navigating the Increasing Complexity of Drug-Biomarker Co-Development
September 10th 2018To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.
Navigating the Complex Reimbursement and Policy Landscape of Healthcare Access
August 13th 2018Tommy Bramley and Kristine Flemister discuss today’s increasingly complex healthcare environment, and share insights into how stakeholders should be evolving to better help patients and providers navigate barriers around access and affordability.
Piecing Together the Pricing Puzzle: The Midterm Elections
June 10th 2018There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.
Patient Adherence and Human Nature
April 15th 2018With less than 50% of patients with long-term conditions remaining adherent to their recommended treatment, we need to look to behavioral science to deconstruct the barriers that make people act in ways that can seem self-defeating, writes Jim O'Donaghue.
Pharm Exec's 16th Annual Industry Audit
September 22nd 2017With our latest review indicating declines in shareholder value and shareholder value to sales, those companies that score well in critical profit management metrics such as return on invested capital are best positioned to maintain that crucial edge in performance execution.